If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The writer finds himself fighting for survival against zombies, going through the church grounds, passing a swamp, running in a volcano rift (called Devil's rift), driving a train through tracks full of zombies, and finally getting into the town, where finds the BMRF radio station and the police station, his main destination. To make things worse, the police who have been sent to investigate the strange happenings have also been turned into zombies and are still capable of using weapons and equipment, and prove to be a constant threat (as well as a source of ammunition). Once the player gets into town, he uses the local radio station to call for the state police. In the end, the player is captured by the undead sheriff and imprisoned. The episode ends with a zombie approaching his cell door to eat him.
Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. The combination contains insulin icodec, a basal insulin analog; and semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Insulin icodec regulates glucose metabolism by binding to insulin receptors. Semaglutide regulates insulin and glucagon secretion in a glucose-dependent manner by selectively binding to and activating the GLP-1 receptor, the target for native GLP-1.
Ghana has a universal health care system, National Health Insurance Scheme (NHIS), which is strictly designated for Ghanaian nationals. Health care is variable throughout Ghana and in 2012, more than 12 million Ghanaian nationals were covered by the NHIS. Urban centres are served and contain most of the hospitals, clinics, and pharmacies. There are more than 200 hospitals, and Ghana is a destination for medical tourism. In 2010, there were 0.1 physicians per 1,000 people and as of 2011, 0.9 hospital beds per 1,000 people. In 2010, 5.2% of Ghana's GDP was spent on health. In 2020, the WHO announced Ghana became the second country in the WHO African Region to attain regulatory system "maturity level 3", the second-highest in the four-tiered WHO classification of National medicines regulatory systems. Life expectancy at birth in 2021 was 68.6 for a female and 63.7 for a male. In 2013, infant mortality was to 39 per 1,000 live births. Sources vary on life expectancy at birth; the World Health Organization (WHO) estimated 64 years for women and 62 years for men born in 2016. The fertility rate declined from 3.99 (2000) to 3.28 (2010) with 2.78 in urban region and 3.94 in rural region. The United Nations reports a fertility decline from 6.95 (1970) to 4.82 (2000) to 3.93 live births per woman in 2017. As of 2012, the HIV/AIDS prevalence was estimated at 1.40% among adults aged 15–49.
Sources: en.wikipedia.org
== External links == Images of fruit development from flowers at bioimages.Vanderbilt.edu (archived 18 February 2007) Fruit and seed dispersal images at bioimages.Vanderbilt.edu (archived 25 April 2017) Fruit Facts (Archived 2020-07-12 at the Wayback Machine from California Rare Fruit Growers, Inc.) Photo ID of Fruits (Archived 2021-01-09 at the Wayback Machine by Capt. Pawanexh Kohli) "Fruit" . Encyclopædia Britannica (11th ed.). 1911.
=== Tempe kering === Also known as kering tempe (lit: 'dry tempeh'), or sambal goreng tempe if mixed with plenty of hot and spicy sambal chili pepper sauce. It is a crispy, sweet and spicy, fried tempeh. The raw tempeh is cut into small sticks and thoroughly deep-fried until no longer moist, and then mixed with palm sugar, chili pepper or other spices, or with sweet soy sauce. Often it is mixed with separately fried peanuts and anchovies (ikan teri). This dry tempeh will keep for up to a month if cooked and stored properly.
Even after the Meiji era when hybrid cattle were encouraged, there were still a considerable number of pure Wagyu cattle remaining in the Taisho era (1912–1926). As a policy for the improvement of Wagyu, efforts were made to eliminate negative characteristics of hybrid cattle as much as possible. Specifically, the elimination of sudare (tiger stripes), nori-kuchi (grayish-white lips), unagi-sen (different fur color on the dorsal line), white spots, etc. On the other hand, efforts were made to improve the physique and weight of both pure and improved Wagyu cattle, and from around the 1920s, the term "improved Wagyu" came to refer to all Wagyu cattle, including not only improved Wagyu but also pure Wagyu. Around 1919, the examination and registration of Wagyu began mainly in western Japan, and pedigrees and body types began to be registered. Nine breeds were registered: Tajima, Bisaku, Hiroshima, Bocho, Shimane, Inhaku, Bungo, Kumamoto, and Kagoshima. However, the examination and registration process was carried out by each prefecture, and the criteria for examination varied. Around 1925, the results of the improvements became visible: the negative characteristics of crossbreeding had almost disappeared from Wagyu cattle, their size and weight had increased, and improvements in hindquarters were clearly visible.
T cell development in the thymus. Video by Janice Yau, describing stromal signaling and tolerance. Department of Immunology and Biomedical Communications, University of Toronto. Master's Research Project, Master of Science in Biomedical Communications. 2011.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.